Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer

키워드

참고문헌 (83)

1. Siegel RL, "Cancer statistics, 2019", CA Cancer J Clin, 69, pp.7~34 (2019)
2. Sudo T, "Molecular-targeted therapies for ovarian cancer : prospects for the future", Int J Clin Oncol, 17, pp.424~429 (2012)
3. Hennessy BT, "Ovarian cancer", Lancet, 374, pp.1371~1382 (2009)
4. Webb PM, "Epidemiology of epithelial ovarian cancer", Best Pract Res Clin Obstet Gynaecol, 41, pp.3~14 (2017)
5. 박정애, "Hippo-YAP", TAZ signaling in angiogenesis, 2018, pp.51(3), 157~162[DOI]
6. Folkman J, "Role of angiogenesis in tumor growth and metastasis", Semin Oncol, 29, pp.15~18 (2002)
7. Masabumi Shibuya, "Vascular endothelial growth factor-dependent and-independent regulation of angiogenesis", BMB reports, 41(4), pp.278~286 (2008), 한국생화학분자생물학회
8. Ribatti D, "Limitations of Anti-Angiogenic Treatment of Tumors", Transl Oncol, 12, pp.981~986 (2019)
9. Dunleavey JM, "Vascular Mimicry : Concepts and Implications for Anti-Angiogenic Therapy", Curr Angiogenes, 1, pp.133~138 (2012)
10. Maniotis AJ, "Vascular channel formation by human melanoma cells in vivo and in vitro : vasculogenic mimicry", Am J Pathol, 155, pp.739~752 (1999)
11. Zhang X, "Molecular Mechanisms and Anticancer Therapeutic Strategies in Vasculogenic Mimicry", J Cancer, 10, pp.6327~6340 (2019)
12. Sood AK, "The clinical significance of tumor cell-lined vasculature in ovarian carcinoma : implications for anti-vasculogenic therapy", Cancer Biol Ther, 1, pp.661~664 (2002)
13. 박영숙, "Regulation of IL-6 signaling by miR-125a and let-7e in endothelial cells controls vasculogenic mimicry formation of breast cancer cells", BMB Reports, 52(3), pp.214~219 (2019), 생화학분자생물학회[DOI]
14. Fan YL, "A new perspective of vasculogenic mimicry : EMT and cancer stem cells(Review)", Oncol Lett, 6, pp.1174~1180 (2013)
15. Yu L, "Evaluation of the correlation of vasculogenic mimicry, ALDH1, KiSS-1, and MACC1 in the prediction of metastasis and prognosis in ovarian carcinoma", Diagn Pathol, 12, pp.23~ (2017)
16. Liang J, "Association of Vasculogenic Mimicry Formation and CD133 Expression with Poor Prognosis in Ovarian Cancer", Gynecol Obstet Invest, 81, pp.529~536 (2016)
17. 채영찬, "Cancer stem cell metabolism: target for cancer therapy", BMB Reports, 51(7), pp.319~326 (2018), 생화학분자생물학회
18. Zhang D, "Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer", Mol Cancer, 13, pp.207~ (2014)
19. Xu Y, "Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis", J Exp Clin Cancer Res, 31, pp.16~ (2012)
20. Carmeliet P, "Angiogenesis in life, disease and medicine", Nature, 438, pp.932~936 (2005)
21. Boocock CA, "Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma", J Natl Cancer Inst, 87, pp.506~516 (1995)
22. Chen Y, "VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer", Cell Mol Biol Lett, 23, pp.2~ (2018)
23. Wang JY, "Functional significance of VEGF-a in human ovarian carcinoma : role in vasculogenic mimicry", Cancer Biol Ther, 7, pp.758~766 (2008)
24. Reinthaller A, "Antiangiogenic therapies in ovarian cancer", Memo, 9, pp.139~143 (2016)
25. Markowska A, "Angiogenesis and cancer stem cells : New perspectives on therapy of ovarian cancer", Eur J Med Chem, 142, pp.87~94 (2017)
26. Richardson DL, "New and Novel Therapies for Gynecologic Cancers", Semin Oncol Nurs, 35, pp.217~219 (2019)
27. Cortez AJ, "Advances in ovarian cancer therapy", Cancer Chemother Pharmacol, 81, pp.17~38 (2018)
28. Wedge SR, "AZD2171 : a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer", Cancer Res, 65, pp.4389~4400 (2005)
29. Ledermann JA, "Cediranib in patients with relapsed platinum-sensitive ovarian cancer(ICON6) : a randomised, double-blind, placebo-controlled phase 3 trial", Lancet, 387, pp.1066~1074 (2016)
30. Raja FA, "Initial toxicity assessment of ICON6 : a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer", Br J Cancer, 105, pp.884~889 (2011)
31. Pick AM, "Pazopanib for the treatment of metastatic renal cell carcinoma", Clin Ther, 34, pp.511~520 (2012)
32. Schoffski P, "Pazopanib in the treatment of soft tissue sarcoma", Expert Rev Anticancer Ther, 12, pp.711~723 (2012)
33. Pignata S, "Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer(MITO 11) : a randomised, open-label, phase 2trial", Lancet Oncol, 16, pp.561~568 (2015)
34. du Bois A, "Incorporation of pazopanib in maintenance therapy of ovarian cancer", J Clin Oncol, 32, pp.3374~3382 (2014)
35. Floquet A, "Progressionfree survival by local investigator versus independent central review : comparative analysis of the AGO-OVAR16Trial", Gynecol Oncol, 136, pp.37~42 (2015)
36. Awasthi N, "Profile of nintedanib in the treatment of solid tumors : the evidence to date", Onco Targets Ther, 8, pp.3691~3701 (2015)
37. Hughes G, "Real World Experiences : Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis", J Clin Med, 5, pp.78~89 (2016)
38. du Bois A, "Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer(AGO-OVAR 12) : a randomised, double-blind, placebo-controlled phase 3trial", Lancet Oncol, 17, pp.78~89 (2016)
39. Monk BJ, "Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer(TRINOVA-1) : a randomised, multicentre, double-blind, placebo-controlled phase 3 trial", Lancet Oncol, 15, pp.799~808 (2014)
40. van Beijnum JR, "The great escape; the hallmarks of resistance to antiangiogenic therapy", Pharmacol Rev, 67, pp.441~461 (2015)
41. Sood AK, "Molecular determinants of ovarian cancer plasticity", Am J Pathol, 158, pp.1279~1288 (2001)
42. 조하늘, "Endothelial miR-26a regulates VEGF-Nogo-B receptor-mediated angiogenesis", BMB Reports, 50(7), pp.384~389 (2017), 생화학분자생물학회
43. Carmeliet P, "Molecular mechanisms and clinical applications of angiogenesis", Nature, 473, pp.298~307 (2011)
44. Hendrix MJ, "Expression and functional significance of VE-cadherin in aggressive human melanoma cells : role in vasculogenic mimicry", Proc Natl Acad Sci U S A, 98, pp.8018~8023 (2001)
45. Du J, "Hypoxia promotes vasculogenic mimicry formation by inducing epithelialmesenchymal transition in ovarian carcinoma", Gynecol Oncol, 133, pp.575~583 (2014)
46. Liu W, "MicroRNA-27b functions as a new inhibitor of ovarian cancer-mediated vasculogenic mimicry through suppression of VE-cadherin expression", RNA, 23, pp.1019~1027 (2017)
47. Czekierdowski A, "Mig-7 expression and vasculogenic mimicry in malignant ovarian tumors", Ginekol Pol, 88, pp.552~561 (2017)
48. Lapeyre-Prost A, "Immunomodulatory Activity of VEGF in Cancer", Int Rev Cell Mol Biol, 330, pp.295~342 (2017)
49. 정민석, "Vascular endothelial growth factor improves the therapeutic effects of cyclodextrin in Niemann-Pick type C mice", Animal Cells and Systems, 23(5), pp.346~354 (2019), 한국통합생물학회[DOI]
50. Mei J, "VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro", Exp Oncol, 30, pp.29~34 (2008)
51. Qin L, "Peroxisome proliferator-activated receptor gamma ligands inhibit VEGF-mediated vasculogenic mimicry of prostate cancer through the AKT signaling pathway", Mol Med Rep, 10, pp.276~282 (2014)
52. Cong R, "Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells", J Exp Clin Cancer Res, 28, pp.124~ (2009)
53. Cheng N, "Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis", Mol Cancer Res, 1, pp.2~11 (2002)
54. 사랄라 마난다, "Emerging role of RUNX3 in the regulation of tumor microenvironment", BMB Reports, 51(4), pp.174~181 (2018), 생화학분자생물학회
55. Zimna A, "Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis : Applications and Therapies", Biomed Res Int, 2015, pp.549412~ (2015)
56. Kaiyuan Yu, "HIF1α promotes prostate cancer progression by increasing ATG5 expression", Animal Cells and Systems, 23(5), pp.326~334 (2019), 한국통합생물학회[DOI]
57. Zhang S, "Vasculogenic mimicry : current status and future prospects", Cancer Lett, 254, pp.157~164 (2007)
58. Sun B, "Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma", Cancer Lett, 249, pp.188~197 (2007)
59. Su M, "Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo", Int J Gynecol Cancer, 18, pp.476~486 (2008)
60. Herr F, "HCG in the regulation of placental angiogenesis. Results of an in vitro study", Placenta, 28(Suppl A), pp.S85~S93 (2007)
61. Muller CY, "The quagmire of hCG and hCG testing in gynecologic oncology", Gynecol Oncol, 112, pp.663~672 (2009)
62. Su M, "Role of hCG in vasculogenic mimicry in OVCAR-3 ovarian cancer cell line", Int J Gynecol Cancer, 21, pp.1366~1374 (2011)
63. Gao S, "Effects of HCG on human epithelial ovarian cancer vasculogenic mimicry formation in vivo", Oncol Lett, 12, pp.459~466 (2016)
64. Qiao L, "XIAP-associated factor 1(XAF1)suppresses angiogenesis in mouse endothelial cells", Tumour Biol, 29, pp.122~129 (2008)
65. Zhu LM, "Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma", Oncotarget, 5, pp.5403~5415 (2014)
66. Vartanian AA, "The involvement of apoptosis in melanoma vasculogenic mimicry", Melanoma Res, 17, pp.1~8 (2007)
67. Wang Y, "Role of Xlinked inhibitor of apoptosisassociated factor1 in vasculogenic mimicry in ovarian cancer", Mol Med Rep, 16, pp.325~330 (2017)
68. Dejana E, "The role of wnt signaling in physiological and pathological angiogenesis", Circ Res, 107, pp.943~952 (2010)
69. 김남희, "Dishevelling Wnt and Hippo", BMB Reports, 51(9), pp.425~426 (2018), 생화학분자생물학회
70. Qi H, "Wnt5a promotes vasculogenic mimicry and epithelial-mesenchymal transition via protein kinase Calpha in epithelial ovarian cancer", Oncol Rep, 32, pp.771~779 (2014)
71. Rabbani SA, "The role of the plasminogen activation system in angiogenesis and metastasis", Surg Oncol Clin N Am, 10, pp.393~415 (2001)
72. Tang J, "cRGD inhibits vasculogenic mimicry formation by down-regulating uPA expression and reducing EMT in ovarian cancer", Oncotarget, 7, pp.24050~24062 (2016)
73. Sestito R, "Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis", Life Sci, 159, pp.43~48 (2016)
74. Orecchia P, "L19-IL2Immunocytokine in Combination with the Anti-Syndecan-146F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model", Cancers (Basel), 11, pp.1232~1250 (2019)
75. 김종민, "MicroRNAs as critical regulators of the endothelial to mesenchymal transition in vascular biology", BMB Reports, 51(2), pp.65~72 (2018), 생화학분자생물학회
76. Rosa Hernández, "Downregulated microRNAs in the colorectal cancer: diagnostic and therapeutic perspectives", BMB Reports, 51(11), pp.563~571 (2018), 생화학분자생물학회
77. 서나영, "MicroRNA controls of cellular senescence", BMB Reports, 51(10), pp.493~499 (2018), 생화학분자생물학회
78. Kinose Y, "The role of microRNAs in ovarian cancer", Biomed Res Int, 2014, pp.249393~ (2014)
79. Sun Q, "The role of miR-200a in vasculogenic mimicry and its clinical significance in ovarian cancer", Gynecol Oncol, 132, pp.730~738 (2014)
80. Salinas-Vera YM, "HypoxamiRs Profiling Identify miR-745 as a Regulator of the Early Stages of Vasculogenic Mimicry in SKOV3 Ovarian Cancer Cells", Front Oncol, 9, pp.381~ (2019)
81. Lanqin Cao, "MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition", BMB Reports, 51(9), pp.456~461 (2018), 생화학분자생물학회
82. Choi PW, "The Functions of MicroRNA-200 Family in Ovarian Cancer : Beyond Epithelial-Mesenchymal Transition", Int J Mol Sci, 18, pp.1207~1226 (2017)
83. Monk BJ, "Antiangiogenic agents in ovarian cancer : past, present, and future", Ann Oncol, 27(Suppl 1), pp.i33~i39 (2016)

관련 논문AI추천